Get the Stockscreener App
7.66
0.13%
-0.010
Cvrx Inc stock is traded at $7.66, with a volume of 3,409.
It is down -0.13% in the last 24 hours and down -15.36% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$7.67
Open:
$7.59
24h Volume:
3,409
Relative Volume:
0.02
Market Cap:
$200.77M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-2.8319
EPS:
-2.7049
Net Cash Flow:
$-40.45M
1W Performance:
+6.69%
1M Performance:
-15.36%
6M Performance:
+16.41%
1Y Performance:
-43.13%
1-Day Range:
$7.505
$7.67
1-Week Range:
$6.98
$7.80
52-Week Range:
$4.2993
$18.55
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
7.66 | 201.03M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
128.32 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.31 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.47 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.58 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx’s Barostim therapy receives Category I CPT codes By Investing.com - Investing.com Australia
CVRx, Inc. Announces Transition to Category I CPT Codes for Barostim Therapy Effective January 1, 2026 - Quiver Quantitative
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy - The Manila Times
CVRx signals gratitude towards healthcare community amid heart failure treatment advancements - Traders Union
Institution Moves: Can CVRX stock resist market sell offs2025 Momentum Check & Long-Term Growth Portfolio Plans - moha.gov.vn
Technical Reactions to CVRX Trends in Macro Strategies - Stock Traders Daily
CVRx, Inc.'s (NASDAQ:CVRX) Popularity With Investors Under Threat As Stock Sinks 26% - simplywall.st
CVRx upgraded by William Blair to outperform - MSN
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
CVRx supports St. Cloud Hospital with Barostim implants - Traders Union
CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Why CVRx Inc. stock is a must watch in 2025July 2025 Setups & Community Verified Swing Trade Signals - Улправда
Will CVRX stock reach Wall Street targetsJuly 2025 Recap & Fast Moving Market Watchlists - Bölüm Sonu Canavarı
Why CVRx Inc. stock is favored by pension funds2025 Major Catalysts & Risk Managed Trade Strategies - Улправда
Earnings Report: Will CVRX stock deliver long term returnsJuly 2025 Patterns & Long-Term Capital Growth Strategies - Bollywood Helpline
CVRx marks milestone with 25 Barostim implants at Los Robles - Traders Union
Discipline and Rules-Based Execution in CVRX Response - Stock Traders Daily
Why CVRx Inc. stock remains a top recommendation - Улправда
Is CVRx Inc. stock positioned for long term growthJuly 2025 Market Mood & Daily Profit Maximizing Trade Tips - DonanımHaber
What analyst consensus says on CVRX stock2025 Growth vs Value & Accurate Technical Buy Alerts - Улправда
How resilient is CVRX stock in market downturnsJuly 2025 Big Picture & Precise Buy Zone Identification - DonanımHaber
Analysts Offer Insights on Healthcare Companies: Pulmonx (LUNG), Novan (NOVN) and CVRx (CVRX) - The Globe and Mail
Is CVRX stock a buy on dips2025 Price Momentum & AI Powered Trade Plan Recommendations - Улправда
Earnings Risk: Why CVRx Inc. stock is a must watch in 2025July 2025 Rallies & Stock Portfolio Risk Management - Улправда
How CVRx Inc. stock reacts to Fed rate cutsWeekly Investment Recap & Fast Moving Stock Trade Plans - Улправда
Will CVRX stock outperform tech sector in 2025Earnings Growth Summary & Real-Time Volume Analysis Alerts - Улправда
CVRx hosts webinar on Barostim coding updates ahead of 2026 - Traders Union
CVRx Earnings Notes - Trefis
CVRx prepares for Jan 2026 Barostim billing update - Traders Union
Behavioral Patterns of CVRX and Institutional Flows - news.stocktradersdaily.com
Would You Still Hold CVRx Stock If It Fell Another 30%? - Trefis
Is CVRx Inc. stock supported by strong fundamentals2025 Market Sentiment & Risk Managed Trade Strategies - Newser
Why CVRX stock could rally in 20252025 Institutional Moves & Growth Focused Stock Pick Reports - Newser
Johnson & Johnson's Strategic Adjustment in CVRx Inc Holdings - GuruFocus
Johnson & Johnson sells CVRx (CVRX) shares worth $63,560 - Investing.com India
Johnson & Johnson Makes a Bold Move with CVRx Stock Sale! - TipRanks
Johnson & Johnson sells CVRx (CVRX) shares worth $63,560 By Investing.com - Investing.com Australia
Jobs Data: Will CVRX stock deliver long term returnsMarket Sentiment Review & Capital Efficient Trading Techniques - BỘ NỘI VỤ
CVRX 8-K & SEC Filings - Yahoo Finance
Will CVRX stock deliver long term returnsJuly 2025 Volume & Low Volatility Stock Recommendations - BỘ NỘI VỤ
CVRx stock slides on preliminary revenue miss - MSN
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
CVRx (CVRX) Gets a Buy from Canaccord Genuity - The Globe and Mail
Johnson & Johnson Makes a Strategic Move with CVRx Stock Sale! - TipRanks
CVRx stock holds Buy rating at Canaccord as CMS finalizes 2026 payment - Investing.com Nigeria
Johnson & Johnson innovation sells $27,132 in CVRx shares By Investing.com - Investing.com South Africa
Johnson & Johnson innovation sells $27,132 in CVRx shares - Investing.com India
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 06 '25 |
Sale |
10.21 |
52,332 |
534,310 |
4,051,098 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 07 '25 |
Sale |
10.00 |
200 |
2,000 |
4,050,898 |
| Nielsen Kirk G. | Director |
May 15 '25 |
Buy |
5.45 |
10,966 |
59,795 |
1,910,134 |
| Nielsen Kirk G. | Director |
May 13 '25 |
Buy |
5.29 |
101,413 |
536,313 |
1,837,968 |
| Nielsen Kirk G. | Director |
May 14 '25 |
Buy |
5.23 |
61,200 |
320,364 |
1,899,168 |
| Nielsen Kirk G. | Director |
May 12 '25 |
Buy |
4.79 |
25,200 |
120,670 |
1,736,555 |
| Jain Mudit K. | Director |
May 12 '25 |
Buy |
4.66 |
1,500 |
6,986 |
4,900 |
0.45%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):